Authors: Hatzelmann, A Schudt, C

Citation: A. Hatzelmann et C. Schudt, Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro, J PHARM EXP, 297(1), 2001, pp. 267-279

Authors: Bundschuh, DS Eltze, M Barsig, J Wollin, L Hatzelmann, A Beume, R

Citation: Ds. Bundschuh et al., In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor, J PHARM EXP, 297(1), 2001, pp. 280-290

Authors: Van der Mey, M Hatzelmann, A Van der Laan, IJ Sterk, GJ Thibaut, U Timmerman, H

Citation: M. Van Der Mey et al., Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues, J MED CHEM, 44(16), 2001, pp. 2511-2522

Authors: Van der Mey, M Hatzelmann, A Van Klink, GPM Van der Laan, IJ Sterk, GJ Thibaut, U Ulrich, WR Timmerman, H

Citation: M. Van Der Mey et al., Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones, J MED CHEM, 44(16), 2001, pp. 2523-2535

Authors: Galle, J Zabel, U Hubner, U Hatzelmann, A Wagner, B Wanner, C Schmidt, HHHW

Citation: J. Galle et al., Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone,cyclic GMP levels and phosphodiesterase activity, BR J PHARM, 127(1), 1999, pp. 195-203